Navigation Links
Anterios, Inc. CEO And Founder, Jon Edelson, To Present At Needham & Company's 12th Annual Healthcare Conference
Date:4/29/2013

NEW YORK, April 29, 2013 /PRNewswire/ -- Anterios, Inc., a privately held aesthetic medicine and medical dermatology biopharmaceutical company, announced today that CEO and Founder, Jon Edelson , MD will be presenting at Needham & Company's 12th Annual Healthcare Conference in New York City on April 30, 2013. Dr. Edelson will be joining a roster of presenters that includes senior management from some of the most well respected public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology, and Diagnostics sectors.

"I'm looking forward to presenting at Needham's Annual Healthcare Conference and sharing with the investment community the latest company news from Anterios," stated Dr. Edelson.  "We are at an important phase of our clinical development with ANT-1207, our topical botulinum prescription product.  ANT-1207 has true potential for expanding the aesthetic and medical dermatology marketplace."

About ANT-1207
ANT-1207, Botulinum Toxin Type A, Topical Lotion, is an investigational product being developed for the potential treatment of facial wrinkles, hyperhidrosis (excessive sweating) and other FDA-approved clinical indications for injectable botulinum as well as new potential clinical indications such as acne. The Company believes that this treatment has the potential to greatly expand the market for botulinum as it would overcome the limitations of injection, which include pain, bleeding and bruising as well as the potential for needle misplacement.

ANT-1207 is a lotion that takes five to ten minutes to apply in the physician's office, where it is fully massaged into the skin. Unlike many botulinum-based products, ANT-1207 does not require reconstitution in the physician's office prior to use, making it convenient and time-saving for the physician and the physician's staff. ANT-1207 incorporates a highly purified botulinum developed from Anterios' proprietary cell line of C. Botulinum Type A.  

ANT-1207 has been studied for the indications of lateral canthal lines (Crow's Feet wrinkles), hyperhidrosis and acne in multi-center, double-blind, randomized, controlled, dose-escalation studies enrolling approximately 250 subjects. These studies demonstrated that ANT-1207 was well tolerated and demonstrated clinically and statistically significant efficacy versus controls. The Company is currently conducting Phase 2b clinical trials on ANT-1207.

About Anterios, Inc.
Anterios, Inc. ("Anterios") is a privately held clinical stage biopharmaceutical company which is developing next generation botulinum-based prescription products for aesthetic medicine and dermatology. Anterios has developed a proprietary platform technology that enables local, targeted delivery of botulinum toxin and other macromolecules across the skin without needles or other invasive treatments that can be destructive to the skin. In the future, Anterios plans to develop additional dermatology products to topically deliver other active ingredients, as well as products for delivery by other modalities. More information can be found at www.anteriosinc.com.


'/>"/>
SOURCE Anterios, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anterios, Inc., Announces Corporate Financing To Further Clinical Development Of Its Topical Botulinum Product
2. Rush University Medical Center Presents Positive MuGard Clinical Data at the Oncology Nursing Society 38th Annual Congress
3. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4. Cempra to Present Data on Solithromycins (CEM-101) Potential Against Urogenital Infections and Multidrug-Resistant Pathogens at ECCMID
5. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
6. NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference
7. Lexicon To Present At The Needham Healthcare Conference
8. Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference
9. KaloBios to Present at Needham Healthcare Conference
10. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
11. MEI Pharma CEO To Present At Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):